நோய் எதிர்ப்பு சக்தி பதில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bavarian Nordic, BioCryst Pharmaceuticals, Integrated Biotherapeutics, Geovax, Batavia Biosciences, Globavir Biosciences, Collaboration Pharmaceuticals, Emergex Vaccines, ReiThera, Emergent BioSolutions, Mapp Biopharmaceuticals, Biofactura, Alkido Pharma, Flow Pharma, and others are developing potential drug candidates to improve the Marburg Virus Disease treatment scenario.  BioCryst is developing galidesivir in partnership with U.S. government agencies and other institutions. In September 2013, the National Institute of Allergy and Infectious Diseases (NIAID) contracted with BioCryst to develop galidesivir to treat Marburg virus disease and potentially for other filoviruses, including the Ebola virus. Integrated BioTherapeutics Inc. (IBT), in May 2021, announced the receipt of a contract valued at up to USD 16.3 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop IBT-T03H, a monoclonal an

United statesShruti thakurLos angelesAlkido pharmaGlobavir biosciencesUniversity collaborations licensing partnering analysisNational institute of allergyMapp biopharmaceutical incBiotherapeutics incPublic health agency of canadaUs defense threat reduction agencyCollaboration pharmaceuticalsMarburg virus disease key companiesBiomedical advanced researchNational institutes of healthHuman services